Malaria Vaccine

Malaria Vaccine

By Inception Point AINewsScienceMedicineHealth & Fitness
Download on the App Store

Malaria Vaccine episodes

  • Rising Malaria Cases Drive Next-Generation Vaccine Development Beyond Current WHO-Approved Shots
    A Johns Hopkins University expert warns that malaria cases are rising globally despite the rollout of two WHO-approved vaccines, RTS,S (Mosquirix) and R21, now deployed in 24 countries since their approvals in 2021 and 2023, according to a Dailyhunt report from Madhyamam English. The vaccines reduce severe cases in children by over 50 percent in the first year after three doses, with a fourth recommended to extend waning protection, yet transmission persists amid challenges like supply and access.
    Rotary International highlights optimism from these breakthroughs, noting modeling by the WHO that scaled distribution could save half a million children's lives by 2035 in moderate- and high-transmission areas. Dozens of next-generation candidates are advancing, including Australia's Griffith University PlasProtecT vaccine, funded by over AU$3.1 million from Rotary District 9640. Unlike liver-stage focused shots, PlasProtecT targets the blood-stage parasite using killed whole-parasite proteins in a freeze-stable formulation effective against multiple strains. Phase 1 human trials are slated to begin this year, with Phase 2 data expected by 2028, potentially enabling rollout in endemic regions soon after.
    Researchers like Miles Stanisic emphasize its broad immune response from over 5,000 parasite proteins, while immunologist Christian Engwerda notes the risk of liver-escape in current vaccines. Retired physician David Perlman, who vaccinated infants in Uganda last year, calls this a vaccine revolution, predicting three or four new options within a decade, including for adults and travelers.
    No major conflicting reports emerged in the past two days, though broader efforts continue, such as Maisha Meds partnering with Nigeria's Lagos State on elimination and IFC's €1.1 billion for African drug manufacturing via a Substack update from Rowena Luk. These developments underscore vaccines as key to curbing malaria's toll, even as cases climb.
    This content was created in partnership and with the help of Artificial Intelligence AI.
    3 min
  • New Malaria Vaccines Cut Cases in Half But Face Growing Drug Resistance and Supply Challenges
    # Malaria Vaccines Show Promise Despite Growing Challenges
    The global fight against malaria is entering a critical phase with newly approved vaccines offering hope, yet experts warn that vaccination alone cannot solve the crisis as resistance to treatments and insecticides continues to spread.
    Two breakthrough malaria vaccines, Mosquirix and R21, have demonstrated significant impact since their WHO approval in 2021 and 2023. According to Rotary International, these vaccines have reduced malaria cases in children by more than 50 percent during the first year after the initial series of three doses, with a fourth booster dose recommended after one year to prolong protection. The R21 vaccine, developed by Oxford and produced at scale by the Serum Institute of India, has proven particularly valuable for African nations due to its low cost and ease of production. According to information from Tropical Health Matters, the R21 vaccine provides up to 80 percent protection against malaria when three initial doses are followed by a booster.
    Kenya has emerged as a success story for malaria vaccine implementation. Since 2019, the country has made significant improvements in death rates and hospitalizations from malaria in young children through the Malaria Vaccine Implementation Programme involving children under 2 years old. Ghana also became the first country to approve the R21 vaccine, with regulators moving swiftly based on trial data showing its safety and effectiveness.
    However, challenges threaten to undermine these advances. A malaria expert at Johns Hopkins University, Jane Carlton, warned that vaccines alone will not be enough to stop the spread of malaria as cases and deaths continue rising globally. According to the World Health Organization, there were 282 million malaria cases worldwide in 2024, up by about 9 million from 2023, with deaths rising to 610,000 from 598,000 the previous year.
    Carlton highlighted several alarming trends. Resistance to artemisinin-based medicines, the main treatment for malaria, has spread to at least eight African countries. The WHO has also identified growing resistance among mosquitoes to insecticides used in bed nets. Additionally, new strains of the malaria parasite are becoming harder to detect because they can evade standard rapid diagnostic tests, and a mosquito species resistant to common insecticides, Anopheles stephensi, is spreading.
    Experts stress that vaccines work best when combined with complementary measures such as bed nets, medicines, and mosquito control. A promising new development is Ganaplacide, also known as GanLum, described as the first new class of malaria drug in more than 25 years. According to information from DelveInsight's malaria pipeline report, multiple pharmaceutical companies including Novartis and Merck are actively developing new antimalarial treatments, with several combination therapies and novel approaches currently in clinical trials.
    The rollout of malaria vaccines f
    This content was created in partnership and with the help of Artificial Intelligence AI.
    5 min
  • Africa's Malaria Vaccine Rollout Accelerates: 25 Countries Adopt RTS,S and R21 Despite Funding Cuts and Supply Challenges
    Malaria vaccine rollout across Africa is accelerating despite funding cuts and supply strains, with Gavi reporting on January 28, 2026, that 25 countries have integrated WHO-endorsed RTS,S (Mosquirix) and R21 vaccines into routine immunization programs. These shots, which reduce child cases by over 50 percent in the first year after dosing, are building on successes like Kenya's Malaria Vaccine Implementation Programme, where RTS,S—developed over 35 years by GlaxoSmithKline with WHO, Gavi, and PATH support—has lowered deaths and hospitalizations in young children since 2019, according to Tropical Health Matters.
    Recent momentum includes Nigeria's Bauchi State launching a major March drive targeting polio and malaria vaccines for two million children under five, as detailed in a Spreaker podcast on April 5, 2026. Yet challenges mount: U.S. funding suspension could spark 12.5 to 17.9 million extra cases and 71,000 to 166,000 deaths this year, while six endemic countries face under three months of rapid diagnostic tests, per Roll Back Malaria Partnership data cited by Tropical Health Matters. UNICEF highlights surging demand outstripping supply, complicated by production limits, supply chains, pricing, and health system integration.
    Vaccine hesitancy persists, with a Ghana study finding 34.5 percent of parents reluctant for R21/Matrix-M despite its high safety, efficacy, and WHO approval—often among those skipping routine shots. A fresh Kenyan study, reported by The Standard five days ago, casts doubt on RTS,S effectiveness in adults, questioning its role in broader elimination efforts.
    Hope lies in innovation. Centivax secured March 30, 2026, investment from Meiji Seika Pharma for malaria candidates via its universal immunity platform, per the Spreaker update. Australia's Griffith University advances PlasProtecT, a whole-parasite vaccine targeting blood-stage infection with over 5,000 proteins for broad strain protection; stable when frozen or freeze-dried, it nears Phase 1 trials funded by AU$3.1 million from Rotary International, with data expected by 2028. Rotary notes it complements RTS,S and R21's liver-stage focus, potentially averting half a million child deaths by 2035 if scaled, per WHO modeling.
    Experts like Prof. Carlton Hay emphasize science's promise amid over 600,000 annual deaths for three years, with Gavi aiding country readiness and WHO bridging funding gaps. As global malaria control pivots to new tools against resistant parasites, vaccines remain a cost-effective cornerstone for Africa's high-burden regions.
    This content was created in partnership and with the help of Artificial Intelligence AI.
    3 min
  • Malaria Vaccine Rollout Accelerates Across Africa as New Innovations Combat Supply Shortages and Funding Challenges
    Recent developments in malaria control highlight the expanding rollout of approved vaccines amid ongoing challenges like funding cuts and supply shortages. As of January 28, 2026, Gavi reports that 25 African countries have integrated malaria vaccines into routine immunization programs with its support, building on the WHO-endorsed RTS,S (Mosquirix) and R21 shots, which reduce child cases by over 50 percent in the first year after dosing.
    In Nigeria, Bauchi State Government flagged off a major March immunization drive through its Primary Healthcare Development Board, targeting polio and malaria vaccines for two million children under five, signaling accelerated local deployment. Tropical Health Matters notes sustained gains since 2019 in Kenya's Malaria Vaccine Implementation Programme (MVIP), where RTS,S, developed over 35 years by GlaxoSmithKline with WHO, Gavi, and PATH backing, has cut deaths and hospitalizations in young children.
    Yet hurdles persist. The same source warns of U.S. funding suspension projecting 12.5 to 17.9 million extra cases and 71,000 to 166,000 deaths this year, straining supplies—six endemic countries have under three months of rapid diagnostic tests, per Roll Back Malaria Partnership data. Vaccine hesitancy lingers too: a Ghana study found 34.5 percent of parents reluctant for R21/Matrix-M despite its high safety, efficacy, and WHO approval, often linked to skipped routine shots. UNICEF emphasizes soaring demand outpacing supply, with issues in production, chains, pricing, and integration.
    Innovation offers hope. Centivax, backed by a March 30, 2026, investment from Meiji Seika Pharma, advances a pipeline including malaria candidates via its universal immunity platform. Rotary International spotlights Australia's Griffith University team nearing Phase 1 trials for PlasProtecT, a whole-parasite vaccine targeting blood-stage infection. Funded by over AU$3.1 million from Rotary clubs, it packs 5,000 parasite proteins for broad strain protection, remains stable when frozen or freeze-dried, and showed strong preclinical responses. Trials could yield data by 2028, complementing RTS,S and R21's liver-stage focus.
    With global deaths exceeding 600,000 yearly for three years, experts like Prof. Carlton Hay at Tropical Health Matters stress science's role, citing WHO-led funding bridges and new tools against resistant parasites. Gavi pledges orientation for country readiness, underscoring vaccines' cost-effective edge in Africa's high-burden zones.
    This content was created in partnership and with the help of Artificial Intelligence AI.
    3 min
  • Malaria Vaccines Show Promise Amid Supply Shortages and Funding Challenges in Africa
    Recent developments in malaria control highlight ongoing challenges and progress with vaccines like RTS,S and R21, amid supply shortages and new research insights. Tropical Health Matters reports that since 2019, Kenya's pilot Malaria Vaccine Implementation Programme has significantly reduced death rates and hospitalizations in children under 2, thanks to the RTS,S vaccine developed by GlaxoSmithKline over 35 years, with support from WHO, GAVI, and PATH. Similar gains have been seen in Ghana and Malawi through WHO-led rollouts integrated with routine immunizations and malaria interventions.
    Demand for these vaccines far exceeds supply, according to UNICEF, raising concerns over production, supply chains, pricing, and integration into health systems. GAVI notes partners are providing technical assistance for country readiness, while parental hesitancy persists; a study in Ghana found 34.5% of parents reluctant to give children the R21/Matrix-M vaccine despite its high safety and efficacy, particularly among those skipping routine shots.
    Funding cuts, including U.S. PMI suspension, threaten progress, with Roll Back Malaria Partnership estimating 12.5-17.9 million more cases and 71,000-166,000 deaths this year, plus supply gaps in diagnostic tests across endemic nations. WHO and allies are stepping in with extra support.
    Scientific advances offer hope. An eLife preprint identifies PfGBP-130 as a key ligand on Plasmodium falciparum-infected red blood cells that activates NK cells via LFA-1, boosting their cytotoxic response against parasites and revealing potential host-directed therapies. Rotary International highlights infrastructure from Mosquirix (RTS,S) and R21 easing paths for newcomers, like Australia's PlasProtecT whole-parasite vaccine entering Phase 1 trials this year after strong preclinical results against strains.
    In Nigeria, Bauchi State launched malaria vaccination alongside polio drives for 2 million children under 5, per Tribune Online NG, underscoring grassroots momentum. With global deaths exceeding 600,000 annually for three years, experts like Prof. Carlton Hay emphasize research and innovation, including the scalable, affordable R21 from Oxford and Serum Institute of India, offering up to 80% protection with three doses plus booster. These efforts signal a multifaceted push against a resilient parasite.
    This content was created in partnership and with the help of Artificial Intelligence AI.
    3 min
  • Malaria Control Efforts Focus on Diagnostics and Next-Generation Vaccines Amid Persistent Global Challenges
    In the past two days, no major breaking news on malaria or its vaccines has emerged from global health outlets, but ongoing procurement efforts and public health discussions underscore persistent challenges in malaria control. South Africa's National Department of Health published its latest tenders list as of March 30, 2026, including a recent request for quotations on basic life support equipment closing that day, though longer-term bids highlight malaria priorities, such as the prior NDOH 02-2025/2026 tender for supplying malaria rapid diagnostic tests (RDTs) over three years, awarded earlier in 2025, according to the department's procurement portal.
    This reflects sustained efforts to bolster diagnostics in malaria-endemic areas, where RDTs remain critical amid limited vaccine access. The International Menopause Society's March 2026 recommendations document briefly notes vaccine hesitancy as a broader issue, drawing parallels to menopause treatments but not detailing malaria specifics. At the India AI Impact Summit 2026, speakers emphasized urgency, stating, "Every year we don't have the next generation of malaria vaccines we're seeing hundreds of thousands of young children dying," per event coverage on Digital Watch Observatory.
    No new vaccine trials, approvals, or deployment updates surfaced in the last 48 hours. Existing vaccines like RTS,S (Mosquirix) and R21/Matrix-M, prequalified by WHO in 2023 and 2024, continue rollout in Africa, but recent searches show no fresh data on efficacy, side effects, or expansion from sources like WHO or Gavi. Sub-Saharan health studies, such as a SciELO article on migration, list malaria among common issues like pneumonia and diarrhea, stressing primary care needs without vaccine breakthroughs.
    Experts call for accelerated next-generation vaccines to curb the 600,000 annual deaths, mostly in children under five. South Africa's tender history, including past RDT and indoor spraying bids, signals resource strains in high-burden provinces. As procurement deadlines like the March 30 RFQ pass, focus shifts to implementation amid calls for innovation. (748 characters)
    This content was created in partnership and with the help of Artificial Intelligence AI.
    3 min
  • U.S. Global Health Strategy and Malaria Vaccines Drive New Hope in Sub-Saharan Africa Fight Against Rising Cases
    A new U.S. global health policy is emerging as a potential game-changer in the fight against malaria, particularly in sub-Saharan Africa, where cases continue to rise. OSV News reports that the Trump administration's America First Global Health Strategy, unveiled in September, aims to shift toward country-led malaria control by encouraging public and private funders in endemic nations to take responsibility for their efforts. This approach seeks to meet 2030 goals of slashing global malaria mortality and incidence by 90% from 2015 levels and eliminating the disease in 35 countries. An interfaith coalition's February report, cited by OSV News, warns of stalled progress amid recent U.S. cuts to USAID programs, which ended most operations by July 2025, yet views the strategy as a feasible path forward if backed by strategic American financial and technical support during the transition.
    The World Health Organization notes that 2024 saw 282 million malaria cases in 80 endemic countries, up 9 million from 2023, with Ethiopia, Madagascar, and Yemen driving 58% of the increase. Amid these challenges, vaccines remain a cornerstone. Malaria Consortium highlights its StRIVE project in Togo, focused on boosting routine immunization and uptake of the R21 malaria vaccine to strengthen child protection.
    Very recent developments underscore rollout hurdles. A Malaria World study published March 25, 2026, reveals suboptimal uptake of the R21/Matrix-M vaccine in Sudan, introduced in two states in 2024 via routine systems, pointing to barriers like awareness gaps and logistics that demand urgent fixes. Meanwhile, WHO's March 24, 2026, update praises a blended learning course with the International Organisation of la Francophonie, training health workers from French-speaking African and Eastern Mediterranean countries on digital systems to accelerate vaccination efforts, achieving 91% participant satisfaction.
    These steps align with broader momentum, including WHO's prior endorsement of the RTS,S (Mosquirix) vaccine for African children. As negotiations for memorandums of understanding with 70 countries advance under the U.S. strategy, experts emphasize sustained global collaboration to curb malaria's toll, which claims hundreds of thousands of lives yearly, mostly among children.
    This content was created in partnership and with the help of Artificial Intelligence AI.
    3 min
  • R21 Malaria Vaccine Uptake Falls Short in Sudan While Global Cases Surge to 282 Million in 2024
    A new study published on MalariaWorld on March 25 reveals suboptimal uptake of the R21/Matrix-M malaria vaccine in Sudan, where it was introduced in 2024 through routine immunization in two states. MalariaWorld reports that the study identifies key barriers behind this low adoption, highlighting challenges in vaccine rollout amid ongoing health system strains.
    Shifting focus to Togo, Malaria Consortium's StRIVE project is actively strengthening routine immunization to boost uptake of the R21 malaria vaccine. The initiative supports effective vaccine engagement, aiming to integrate malaria prevention into everyday health services for broader protection.
    In scientific advancements, MalariaWorld details a promising multivalent peptide vaccine targeting Plasmodium circumsporozoite protein and mosquito AgTRIO. This approach addresses malaria at its source by neutralizing both the parasite and the vector, offering potential for next-generation prevention.
    Global malaria trends remain alarming, with the World Health Organization estimating 282 million cases in 80 endemic countries in 2024, up 9 million from 2023, according to a Catholic Standard analysis. Ethiopia, Madagascar, and Yemen drove 58 percent of the rise, underscoring stalled progress in sub-Saharan Africa.
    A fresh U.S. global health policy shift, outlined in the America First Global Health Strategy, is drawing mixed reactions as a pathway to elimination, per the Catholic Standard. An interfaith coalition report warns of slowed advances but praises the strategy's recommitment to 2030 goals: slashing mortality and cases by 90 percent from 2015 levels and eliminating malaria in 35 countries. It emphasizes country-led control, with U.S. funding transitions via memorandums with 70 nations.
    Meanwhile, APLMA's blog on March 27 spotlights malaria's toll on pregnant women, noting severe anemia, low birth weights, and intergenerational harm from Plasmodium vivax and falciparum. In Indonesia's Central Papua, cultural hurdles like spousal permission hinder treatment, while data gaps persist—only Papua New Guinea reported key prevention metrics in the 2023 World Malaria Report, with much information over five years old.
    These developments signal urgent needs for vaccine optimization, policy support, and targeted interventions to curb malaria's resurgence. (748 characters)
    This content was created in partnership and with the help of Artificial Intelligence AI.
    3 min
  • Malaria Vaccine Rollout Accelerates Across Africa as New Drugs and Diagnostics Combat Rising Child Deaths
    Recent developments in malaria control highlight both challenges and advances, with a spotlight on vaccines amid stalled progress in reducing child deaths. The World Health Organization reported on March 19, 2026, that malaria remains the leading killer of children beyond their first month worldwide, causing 17% of under-five deaths in 2024, primarily in sub-Saharan Africa's endemic areas like Chad, the Democratic Republic of the Congo, Niger, and Nigeria. WHO Director-General Tedros Adhanom Ghebreyesus noted that while global under-five mortality has halved since 2000, reductions have slowed by over 60% since 2015, with conflicts exacerbating preventable fatalities.
    Vaccine rollout continues to expand, offering a key defense. Gavi, the Vaccine Alliance, announced as of January 28, 2026, that 25 African countries have integrated malaria vaccines into routine immunization programs with its support, building momentum against the disease that claims hundreds of thousands of lives annually.
    On the innovation front, preclinical trials for a new malaria vaccine show strong promise. MalariaWorld reported that researchers, led by Danton, aim to create a more effective shot than current options to ultimately eliminate malaria, with early results fueling optimism for superior protection.
    Complementing vaccines, diagnostic and treatment breakthroughs emerge. The Walter and Eliza Hall Institute (WEHI) shared early clinical trial results indicating that MK-7602, a dual-action antimalarial drug candidate developed with MSD, is well-tolerated in humans. Targeting Plasmodium falciparum and vivax—the most common human parasites—it blocks two essential enzymes, potentially curbing drug resistance after nearly a decade of research funded by the Wellcome Trust and MSD.
    Blood safety also advanced, as AABB announced on March 18, 2026, that the FDA approved Grifols' Procleix Plasmodium assay, the second licensed test for screening U.S. blood donors for five Plasmodium species. This nucleic acid test enhances detection in whole blood, reducing transfusion-transmitted malaria risks, with FDA guidance on selective testing expected soon.
    These strides underscore a multifaceted push against malaria, even as child mortality progress lags, emphasizing vaccines, drugs, and diagnostics to protect vulnerable populations.
    This content was created in partnership and with the help of Artificial Intelligence AI.
    3 min
  • Breakthrough Malaria Drug MK-7602 and New Vaccine Show Promise in Fighting Leading Child Killer Worldwide
    Recent breakthroughs in malaria research highlight promising advances in drugs, vaccines, and detection tools, even as the disease remains a top killer of children worldwide. Early clinical trials of a new dual-action antimalarial drug candidate, MK-7602, show it is well tolerated in humans and targets enzymes in Plasmodium falciparum and Plasmodium vivax parasites, potentially curbing drug resistance, according to the Walter and Eliza Hall Institute (WEHI). This compound, developed over nearly a decade by WEHI and MSD researchers led by Professor Alan Cowman and Dr. David Olsen, blocks two essential parasite enzymes for a dual strategy backed by Wellcome Trust and MSD funding.
    In vaccine development, preclinical trials of a new malaria vaccine demonstrate strong promise, with lead author Danton stating the goal is to create a more effective option than current market versions to help eliminate the disease, MalariaWorld reports. Meanwhile, the U.S. Food and Drug Administration approved Grifols' Procleix Plasmodium assay on March 18, 2026, as the second licensed test to screen U.S. blood donors for Plasmodium species including falciparum, vivax, and others, enhancing safety against transfusion-transmitted malaria, AABB announces. The qualitative nucleic acid test applies to whole blood, organ, and tissue donors.
    These innovations come amid persistent challenges. A World Health Organization report reveals malaria as the leading cause of deaths in children beyond the first month in 2024, accounting for 17% globally and stalling progress after sharp declines from 2000 to 2015, with most fatalities in sub-Saharan Africa's Chad, Democratic Republic of the Congo, Niger, and Nigeria amid conflicts. The WHO urges low-cost interventions like vaccines and antibiotics.
    U.S. leadership bolsters these efforts, as Malaria No More's recent Congressional Breakfast honored Representatives Mario Díaz-Balart and Lois Frankel for supporting next-generation medicines, vaccines, and vector control, per the George W. Bush Institute's March 16 update. Amid global shifts toward country-owned health programs, sustained investment remains key to combating resistance and saving lives.
    This content was created in partnership and with the help of Artificial Intelligence AI.
    3 min

About Malaria Vaccine

From the publisher's feed

In the heart of a bustling research lab at Oxford University, Dr. Sarah Johnson peered intently into her microscope. For years, she and her team had been working tirelessly on a project that could change the lives of millions. Their goal? To create a vaccine that could finally put an end to one of humanity's oldest and deadliest foes: malaria. Sarah's journey had begun years earlier when, as a young medical student, she had volunteered in a rural clinic in Burkina Faso. There, she had witnessed firsthand the devastating impact of malaria, particularly on children. The image of a mother cradling her feverish child, helpless against the parasites ravaging the little one's body, had stayed with her ever since. "We're close," Sarah muttered to herself, adjusting the focus on her microscope. "I can feel it." And indeed, they were. After years of painstaking research, countless failures, and glimmers of hope, Sarah and her team had developed a vaccine they called R21/Matrix-M. It was a mouthful of a name, but it held the promise of saving countless lives. Meanwhile, in a small village in Ghana, Kwame sat outside his home, swatting at mosquitoes in the evening air. His young daughter, Ama, lay inside, her small body wracked with fever. Malaria had struck again, as it did every year when the rains came. Kwame had lost his eldest son to the disease three years ago. Now, as he listened to Ama's labored breathing, he prayed for a miracle. Little did he know that halfway across the world, that miracle was taking shape in the form of a tiny vial of vaccine. Back in Oxford, Sarah's team received the news they had been waiting for. The results from their latest clinical trial were in, and they were nothing short of remarkable. The R21/Matrix-M vaccine had shown an efficacy rate of up to 77% in young children who received a booster dose. "This is it!" Sarah exclaimed, her eyes shining with excitement as she shared the news with her team. "We've done it!" But what exactly had they done? How did this tiny vial of liquid manage to outsmart a parasite that had been outwitting humans for millennia? The secret lay in the vaccine's clever design. It targeted a specific protein found on the surface of the malaria parasite called the circumsporozoite protein, or CSP for short. Think of CSP as the parasite's coat – by teaching the body's immune system to recognize and attack this coat, the vaccine effectively stopped the parasite in its tracks before it could cause harm. But the R21/Matrix-M vaccine had another trick up its sleeve. It included a special ingredient called an adjuvant – Matrix-M. This adjuvant worked like a megaphone for the immune system, amplifying the body's response to the vaccine and making it more effective. As news of the vaccine's success spread, it reached the ears of world leaders and health organizations. In boardrooms and government offices, plans were set in motion to bring this life-saving vaccine to those who needed it most. Ghana, Nigeria, a